ALEC
Alector, Inc.
- Latest sale
- $25k
- Sep 4 · No plan
- Form 4 sales
- 143
- On record
- Form 144 notices
- 17
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineMar 10 2026
Sold 1,000 shares at $2.65 ($3k)
Wong-Sarad Grace, Principal Accounting Officer
10b5-1 planSold 0.9% of holdings ($285k position)106,465 shares left0.2x usual sizeFiling
- 2 Form 4 saleRoutineApr 16 +37 days
Sold 1,820 shares at $2.65 ($5k)
Wong-Sarad Grace, Principal Accounting Officer
10b5-1 planSold 1.7% of holdings ($282k position)104,645 shares left0.4x usual sizeFiling
- 3 Form 4 saleNo planJun 2 +47 days
Sold 19,360 shares at $1.97 ($38k)
Berkley Neil Lindsay, CFO & Chief Business Officer
No 10b5-1 planSold 4.8% of holdings ($787k position)379,900 shares left0.7x usual sizeFiling
- 4 Form 4 saleNo planJun 2 same day
Sold 87,216 shares at $1.97 ($172k)
Rosenthal Arnon, Chief Executive Officer
No 10b5-1 planSold 3.6% of holdings ($4.8M position)2.4M shares left1.7x usual sizeFiling
- 5 Form 4 saleNo planJun 3 +1 day
Sold 9,184 shares at $1.94 ($18k)
Wong-Sarad Grace, Principal Accounting Officer
No 10b5-1 planSold 8.8% of holdings ($203k position)95,461 shares left2.1x usual sizeFiling
- 6 Form 4 saleNo planSep 3 +92 days
Sold 29,251 shares at $2.66 ($78k)
Berkley Neil Lindsay, CFO & Chief Business Officer
No 10b5-1 planSold 7.7% of holdings ($1M position)350,649 shares left1.2x usual sizeFiling
- 7 Form 4 saleNo planSep 3 same day
Sold 72,606 shares at $2.66 ($193k)
Rosenthal Arnon, Chief Executive Officer
No 10b5-1 planSold 3.1% of holdings ($6.3M position)2.3M shares left1.4x usual sizeFiling
- 8 Form 4 saleNo planSep 4 +1 day
Sold 9,446 shares at $2.61 ($25k)
Wong-Sarad Grace, Principal Accounting Officer
No 10b5-1 planSold 8.2% of holdings ($302k position)106,015 shares left2x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (160)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 9,446 | $25k | 8.2% | No plan | SEC |
| Sep 3, 2026 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 72,606 | $193k | 3.1% | No plan | SEC |
| Sep 3, 2026 | Berkley Neil Lindsay | CFO & Chief Business Officer | Form 4 sale | 29,251 | $78k | 7.7% | No plan | SEC |
| Jun 3, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 9,184 | $18k | 8.8% | No plan | SEC |
| Jun 2, 2026 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 87,216 | $172k | 3.6% | No plan | SEC |
| Jun 2, 2026 | Berkley Neil Lindsay | CFO & Chief Business Officer | Form 4 sale | 19,360 | $38k | 4.8% | No plan | SEC |
| Apr 16, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 1,820 | $5k | 1.7% | Routine | SEC |
| Mar 10, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 1,000 | $3k | 0.9% | Routine | SEC |
| Mar 3, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 3,367 | $7k | 3.0% | Routine | SEC |
| Mar 2, 2026 | Berkley Neil Lindsay | CFO & Chief Business Officer | Form 4 sale | 29,649 | $63k | 7.9% | No plan | SEC |
| Mar 2, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 8,071 | $17k | 6.8% | No plan | SEC |
| Mar 2, 2026 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 81,864 | $174k | 3.4% | No plan | SEC |
| Feb 26, 2026 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 4,079 | $10k | 3.3% | Routine | SEC |
| Dec 5, 2025 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 4,753 | $6k | 3.7% | No plan | SEC |
| Dec 3, 2025 | Berkley Neil Lindsay | Chief Bus Ofcr & Interim CFO | Form 4 sale | 37,261 | $42k | 9.1% | No plan | SEC |
| Dec 3, 2025 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 8,056 | $9k | 5.9% | No plan | SEC |
| Dec 3, 2025 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 41,687 | $47k | 7.7% | No plan | SEC |
| Dec 3, 2025 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 104,347 | $117k | 4.1% | Unusual | SEC |
| Sep 2, 2025 | Wong-Sarad Grace | Principal Accounting Officer | Form 4 sale | 5,910 | $15k | 5.4% | No plan | SEC |
| Sep 2, 2025 | Berkley Neil Lindsay | Principal Financial Officer | Form 4 sale | 15,842 | $40k | 4.4% | No plan | SEC |
| Sep 2, 2025 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 23,638 | $59k | 4.2% | No plan | SEC |
| Sep 2, 2025 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 51,562 | $129k | 2.1% | No plan | SEC |
| Aug 26, 2025 | Hammond Paula | Director | Form 4 sale | 14,000 | $33k | 15.7% | Routine | SEC |
| Jun 20, 2025 | Yaffe Kristine | Director | Form 4 sale | 1,000 | $1k | 1.0% | Routine | SEC |
| Jun 2, 2025 | Grasso Marc | Chief Financial Officer | Form 4 sale | 16,488 | $22k | 5.3% | No plan | SEC |
| Jun 2, 2025 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 23,890 | $32k | 4.5% | No plan | SEC |
| Jun 2, 2025 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 52,087 | $70k | 2.1% | No plan | SEC |
| Mar 3, 2025 | Grasso Marc | Chief Financial Officer | Form 4 sale | 18,091 | $27k | 5.5% | Unusual | SEC |
| Mar 3, 2025 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 29,073 | $43k | 5.1% | No plan | SEC |
| Mar 3, 2025 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 40,330 | $59k | 1.6% | No plan | SEC |
| Mar 3, 2025 | Romano Gary | Chief Medical Officer | Form 4 sale | 16,306 | $24k | 4.7% | No plan | SEC |
| Dec 2, 2024 | Grasso Marc | Chief Financial Officer | Form 4 sale | 16,489 | $42k | 4.7% | No plan | SEC |
| Dec 2, 2024 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 52,172 | $131k | 2.0% | No plan | SEC |
| Dec 2, 2024 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 26,500 | $67k | 4.5% | No plan | SEC |
| Dec 2, 2024 | Romano Gary | Chief Medical Officer | Form 4 sale | 14,892 | $38k | 4.1% | No plan | SEC |
| Nov 29, 2024 | Romano Gary | Officer | Form 144 notice | 14,306 | $37k | Notice | SEC | |
| Nov 29, 2024 | Kenkare-Mitra Sara | Officer | Form 144 notice | 25,465 | $66k | Notice | SEC | |
| Nov 29, 2024 | Grasso Marc | Officer | Form 144 notice | 15,842 | $41k | Notice | SEC | |
| Nov 29, 2024 | Rosenthal Arnon | Officer, Director | Form 144 notice | 50,142 | $130k | Notice | SEC | |
| Sep 3, 2024 | Grasso Marc | Chief Financial Officer | Form 4 sale | 7,297 | $36k | 5.3% | No plan | SEC |
| Sep 3, 2024 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 26,499 | $129k | 1.3% | No plan | SEC |
| Sep 3, 2024 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 13,926 | $68k | 4.6% | No plan | SEC |
| Sep 3, 2024 | Romano Gary | Chief Medical Officer | Form 4 sale | 8,478 | $41k | 4.5% | No plan | SEC |
| Aug 22, 2024 | Scheller Richard H | Director | Form 4 sale | 44,250 | $228k | 55.8% | Unusual | SEC |
| Aug 12, 2024 | Hammond Paula | Director | Form 4 sale | 10,500 | $53k | 14.8% | Routine | SEC |
| Aug 12, 2024 | Yaffe Kristine | Director | Form 4 sale | 5,000 | $25k | 6.9% | Routine | SEC |
| Jun 3, 2024 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 25,135 | $121k | 1.3% | No plan | SEC |
| Jun 3, 2024 | Romano Gary | Chief Medical Officer | Form 4 sale | 8,040 | $39k | 4.1% | No plan | SEC |
| Jun 3, 2024 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 13,206 | $63k | 4.1% | No plan | SEC |
| Jun 3, 2024 | Grasso Marc | Chief Financial Officer | Form 4 sale | 6,920 | $33k | 4.8% | Unusual | SEC |
| Mar 4, 2024 | Romano Gary | Chief Medical Officer | Form 4 sale | 6,001 | $42k | 3.0% | No plan | SEC |
| Mar 4, 2024 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 10,169 | $70k | 3.1% | No plan | SEC |
| Mar 4, 2024 | Grasso Marc | Chief Financial Officer | Form 4 sale | 5,716 | $40k | 3.8% | Unusual | SEC |
| Mar 4, 2024 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 18,837 | $130k | 0.9% | Unusual | SEC |
| Dec 4, 2023 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 23,831 | $133k | 1.2% | Unusual | SEC |
| Dec 4, 2023 | Romano Gary | Chief Medical Officer | Form 4 sale | 5,035 | $28k | 2.4% | No plan | SEC |
| Dec 4, 2023 | Grasso Marc | Chief Financial Officer | Form 4 sale | 4,574 | $25k | 2.9% | Unusual | SEC |
| Dec 4, 2023 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 12,519 | $70k | 3.7% | No plan | SEC |
| Dec 1, 2023 | Romano Gary | Officer | Form 144 notice | 5,035 | $28k | Notice | SEC | |
| Dec 1, 2023 | Grasso Marc | Officer | Form 144 notice | 4,574 | $25k | Notice | SEC | |
| Dec 1, 2023 | Kenkare-Mitra Sara | Officer | Form 144 notice | 12,519 | $70k | Notice | SEC | |
| Dec 1, 2023 | Rosenthal Arnon | Officer, Director | Form 144 notice | 23,831 | $133k | Notice | SEC | |
| Sep 11, 2023 | Polaris Venture Management Co. VI, L.L.C. | 10% owner | Form 4 sale | 500,000 | $3M | 4.4% | No plan | SEC |
| Sep 11, 2023 | Mcguire Terrance | Director, 10% owner | Form 4 sale | 500,000 | $3M | 4.4% | No plan | SEC |
| Sep 11, 2023 | Polaris Venture Partners VI (AIV-B), L.P. | Director, 10% Stockholder | Form 144 notice | 93,214 | $559k | Notice | SEC | |
| Sep 11, 2023 | Polaris Venture Partners VI (AIV), L.P. | Director, 10% Stockholder | Form 144 notice | 379,180 | $2.3M | Notice | SEC | |
| Sep 11, 2023 | Polaris Venture Partners Founders' Fund VI, L.P. | Director, 10% Stockholder | Form 144 notice | 27,606 | $166k | Notice | SEC | |
| Sep 5, 2023 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 5,647 | $29k | 0.3% | No plan | SEC |
| Sep 5, 2023 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 6,214 | $32k | 3.4% | No plan | SEC |
| Sep 5, 2023 | Romano Gary | Chief Medical Officer | Form 4 sale | 2,771 | $14k | 2.7% | No plan | SEC |
| Sep 5, 2023 | Grasso Marc | Chief Financial Officer | Form 4 sale | 1,114 | $6k | 3.3% | No plan | SEC |
| Sep 1, 2023 | Rosenthal Arnon | Officer, Director | Form 144 notice | 5,233 | $29k | Notice | SEC | |
| Sep 1, 2023 | Kenkare-Mitra Sara | Officer | Form 144 notice | 5,759 | $32k | Notice | SEC | |
| Sep 1, 2023 | Romano Gary | Officer | Form 144 notice | 2,567 | $14k | Notice | SEC | |
| Jun 2, 2023 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 4,092 | $28k | 2.2% | No plan | SEC |
| Jun 2, 2023 | Grasso Marc | Chief Financial Officer | Form 4 sale | 1,050 | $7k | 3.1% | No plan | SEC |
| Jun 2, 2023 | Romano Gary | Chief Medical Officer | Form 4 sale | 2,617 | $18k | 2.5% | No plan | SEC |
| Jun 2, 2023 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 5,255 | $36k | 0.3% | No plan | SEC |
| Jun 1, 2023 | Kenkare-Mitra Sara | Officer | Form 144 notice | 3,956 | $27k | Notice | SEC | |
| Jun 1, 2023 | Romano Gary | Officer | Form 144 notice | 2,567 | $18k | Notice | SEC | |
| Jun 1, 2023 | Rosenthal Arnon | Officer, Director | Form 144 notice | 5,102 | $35k | Notice | SEC | |
| Mar 17, 2023 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 15,186 | $94k | 0.9% | No plan | SEC |
| Mar 2, 2023 | Romano Gary | Chief Medical Officer | Form 4 sale | 5,383 | $46k | 4.9% | Plan not stated | SEC |
| Mar 2, 2023 | Kenkare-Mitra Sara | President and Head of R&D | Form 4 sale | 10,124 | $84k | 5.1% | Plan not stated | SEC |
| Mar 2, 2023 | Grasso Marc | Chief Financial Officer | Form 4 sale | 1,291 | $11k | 3.6% | Plan not stated | SEC |
| Mar 2, 2023 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 5,849 | $49k | 0.4% | Plan not stated | SEC |
| Sep 2, 2022 | Romano Gary | Chief Medical Officer | Form 4 sale | 2,177 | $23k | 2.4% | Plan not stated | SEC |
| Sep 2, 2022 | King Robert | Chief Development Officer | Form 4 sale | 176 | $2k | 0.0% | Plan not stated | SEC |
| Jun 2, 2022 | King Robert | Chief Development Officer | Form 4 sale | 177 | $2k | 0.0% | Plan not stated | SEC |
| Mar 1, 2022 | King Robert | Chief Development Officer | Form 4 sale | 287 | $4k | 0.1% | Plan not stated | SEC |
| Dec 13, 2021 | Suliman Shehnaaz | President and COO | Form 4 sale | 150,000 | $3.2M | 59.4% | Unusual | SEC |
| Dec 9, 2021 | Suliman Shehnaaz | President and COO | Form 4 sale | 150,000 | $3.4M | 59.4% | Unusual | SEC |
| Dec 1, 2021 | King Robert | Chief Development Officer | Form 4 sale | 250 | $5k | 0.0% | Plan not stated | SEC |
| Nov 11, 2021 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 110,000 | $2.8M | 5.3% | Plan not stated | SEC |
| Nov 9, 2021 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 200,000 | $5M | 23.5% | Plan not stated | SEC |
| Nov 5, 2021 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 200,000 | $5M | 22.7% | Plan not stated | SEC |
| Sep 23, 2021 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 109,625 | $2.8M | 4.5% | Plan not stated | SEC |
| Sep 21, 2021 | Rosenthal Arnon | Chief Executive Officer | Form 4 sale | 200,000 | $5.2M | 7.7% | Plan not stated | SEC |
| Aug 9, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 22,950 | $624k | 8.9% | Plan not stated | SEC |
| Aug 5, 2021 | Scheller Richard H | Director | Form 4 sale | 66,241 | $1.9M | 100.0% | Unusual | SEC |
| Jul 7, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 59,749 | $2.3M | 20.3% | Unusual | SEC |
| Jul 6, 2021 | Yu Calvin | Vice President, Finance | Form 4 sale | 114,174 | $3.7M | 59.8% | Unusual | SEC |
| Jul 2, 2021 | King Robert | Chief Development Officer | Form 4 sale | 60,000 | $1.9M | 10.3% | Unusual | SEC |
| Jul 2, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 56,726 | $1.5M | 19.5% | Unusual | SEC |
| Jun 16, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 34,600 | $764k | 11.2% | Unusual | SEC |
| Jun 8, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 19,175 | $368k | 6.5% | Plan not stated | SEC |
| Jun 2, 2021 | Yu Calvin | Vice President, Finance | Form 4 sale | 1,844 | $33k | 1.4% | Plan not stated | SEC |
| May 21, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 14,975 | $272k | 5.2% | Plan not stated | SEC |
| May 18, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 4,200 | $76k | 1.5% | Plan not stated | SEC |
| Apr 7, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 22,300 | $428k | 9.4% | Plan not stated | SEC |
| Mar 23, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 43,800 | $996k | 17.0% | Unusual | SEC |
| Mar 9, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 19,175 | $347k | 8.2% | Plan not stated | SEC |
| Feb 9, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 19,175 | $399k | 8.2% | Plan not stated | SEC |
| Jan 26, 2021 | Name not stated | Chief Medical Officer | Form 4 sale | 57,308 | $1M | 21.1% | Unusual | SEC |
| Jan 20, 2021 | Paul Robert | Chief Medical Officer | Form 4 sale | 38,567 | $698k | 15.3% | Unusual | SEC |
| Jul 15, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $230k | 4.5% | Plan not stated | SEC |
| Jun 23, 2020 | Mcguire Terrance | Director, 10% owner | Form 4 sale | 4,377 | $138k | 0.0% | Plan not stated | SEC |
| Jun 23, 2020 | Polaris Venture Partners VI (AIV), L.P. | 10% owner | Form 4 sale | 4,377 | $138k | 0.0% | Plan not stated | SEC |
| Jun 15, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $296k | 4.3% | Plan not stated | SEC |
| Jun 3, 2020 | Yu Calvin | Vice President, Finance | Form 4 sale | 1,343 | $42k | 1.2% | Plan not stated | SEC |
| May 15, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $270k | 4.1% | Plan not stated | SEC |
| May 15, 2020 | King Robert | Chief Development Officer | Form 4 sale | 15,000 | $405k | 3.0% | Plan not stated | SEC |
| Apr 16, 2020 | Orbimed Advisors LLC | 10% owner | Form 4 sale | 85,414 | $2M | 4.3% | Plan not stated | SEC |
| Apr 15, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $223k | 3.9% | Plan not stated | SEC |
| Apr 9, 2020 | Orbimed Advisors LLC | 10% owner | Form 4 sale | 379,885 | $9M | 16.5% | Plan not stated | SEC |
| Mar 31, 2020 | Orbimed Advisors LLC | 10% owner | Form 4 sale | 250,000 | $6.1M | 11.0% | Plan not stated | SEC |
| Mar 25, 2020 | Orbimed Advisors LLC | 10% owner | Form 4 sale | 138,653 | $3.4M | 6.2% | Plan not stated | SEC |
| Mar 13, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $229k | 3.8% | Plan not stated | SEC |
| Mar 2, 2020 | Orbimed Advisors LLC | 10% owner | Form 4 sale | 1.9M | $48.7M | 100.0% | Unusual | SEC |
| Feb 14, 2020 | King Robert | Chief Development Officer | Form 4 sale | 15,000 | $443k | 3.0% | Plan not stated | SEC |
| Feb 14, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $295k | 3.7% | Plan not stated | SEC |
| Feb 7, 2020 | Oney Sabah | Chief Business Officer | Form 4 sale | 19,900 | $697k | 3.4% | Plan not stated | SEC |
| Feb 7, 2020 | Yu Calvin | Vice President, Finance | Form 4 sale | 26,654 | $933k | 19.4% | Plan not stated | SEC |
| Feb 6, 2020 | Oney Sabah | Chief Business Officer | Form 4 sale | 16,767 | $504k | 2.7% | Plan not stated | SEC |
| Feb 5, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $321k | 3.5% | Plan not stated | SEC |
| Feb 4, 2020 | Scheller Richard H | Director | Form 4 sale | 10,000 | $297k | 50.0% | Unusual | SEC |
| Feb 4, 2020 | Yu Calvin | Vice President, Finance | Form 4 sale | 63,541 | $1.9M | 33.6% | Unusual | SEC |
| Jan 30, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 8,000 | $224k | 2.8% | Plan not stated | SEC |
| Jan 27, 2020 | Oney Sabah | Chief Business Officer | Form 4 sale | 16,667 | $418k | 2.7% | Unusual | SEC |
| Jan 23, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 6,000 | $146k | 2.1% | Plan not stated | SEC |
| Jan 22, 2020 | King Robert | Chief Development Officer | Form 4 sale | 15,000 | $330k | 2.9% | Plan not stated | SEC |
| Jan 15, 2020 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $187k | 3.5% | Plan not stated | SEC |
| Jan 9, 2020 | Orbimed Capital LLC | 10% owner | Form 4 sale | 379,997 | $7.4M | 90.7% | Unusual | SEC |
| Dec 26, 2019 | Orbimed Advisors LLC | 10% owner | Form 4 sale | 519,385 | $10.2M | 92.8% | Unusual | SEC |
| Dec 17, 2019 | Orbimed Advisors LLC | 10% owner | Form 4 sale | 954,100 | $17.7M | 90.7% | Unusual | SEC |
| Dec 13, 2019 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $200k | 3.4% | Plan not stated | SEC |
| Dec 12, 2019 | Oney Sabah | Chief Business Officer | Form 4 sale | 6,810 | $137k | 1.1% | Unusual | SEC |
| Dec 10, 2019 | Oney Sabah | Chief Business Officer | Form 4 sale | 500 | $10k | 0.1% | Plan not stated | SEC |
| Dec 9, 2019 | Oney Sabah | Chief Business Officer | Form 4 sale | 8,956 | $179k | 1.5% | Plan not stated | SEC |
| Dec 3, 2019 | Yu Calvin | Vice President, Finance | Form 4 sale | 1,315 | $24k | 0.7% | Plan not stated | SEC |
| Nov 15, 2019 | King Robert | Chief Development Officer | Form 4 sale | 7,500 | $119k | 1.4% | Plan not stated | SEC |
| Nov 15, 2019 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $159k | 3.3% | Plan not stated | SEC |
| Oct 15, 2019 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $147k | 3.2% | Plan not stated | SEC |
| Sep 20, 2019 | Oney Sabah | Chief Business Officer | Form 4 sale | 400 | $8k | 0.1% | Plan not stated | SEC |
| Sep 20, 2019 | Paul Robert | Chief Medical Officer | Form 4 sale | 4,000 | $80k | 1.3% | Plan not stated | SEC |
| Sep 16, 2019 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $191k | 3.1% | Plan not stated | SEC |
| Aug 20, 2019 | Paul Robert | Chief Medical Officer | Form 4 sale | 2,000 | $32k | 0.6% | Plan not stated | SEC |
| Aug 19, 2019 | King Robert | Chief Development Officer | Form 4 sale | 7,500 | $113k | 1.4% | Plan not stated | SEC |
| Aug 15, 2019 | Paul Robert | Chief Medical Officer | Form 4 sale | 10,000 | $142k | 3.0% | Plan not stated | SEC |
| Aug 7, 2019 | OrbiMed Capital GP IV LLC | 10% owner | Form 4 sale | 650,000 | $11.6M | 18.0% | Plan not stated | SEC |